NDASUBCUTANEOUSSOLUTION
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
SOMATULINE DEPOT (lanreotide acetate) by Ipsen is lanreotide, the active component of somatuline depot is an octapeptide analog of natural somatostatin. First approved in 2007.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMATULINE DEPOT is a long-acting subcutaneous somatostatin analog containing lanreotide acetate, approved in 2007. It mimics natural somatostatin to inhibit hormone secretion and reduce tumor growth in neuroendocrine tumors and acromegaly. The octapeptide formulation provides extended dosing intervals, improving patient compliance over frequent injections.
$53MPart D
LOE ApproachingModest Medicare utilization (~5,400 claims annually) signals a mature, niche market with limited team expansion opportunity as loss of exclusivity approaches.
Mechanism of Action
Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Started May 2009
115 enrolled
Carcinoid Syndrome
Career Relevance
Working on SOMATULINE DEPOT offers exposure to niche oncology/endocrinology markets, mature product management, and international pricing complexity—valued skills for specialty pharma roles. However, LOE approaching constrains team growth; career advancement favors Commercial and Regulatory professionals managing market decline and generic transition.
Director
Worked on SOMATULINE DEPOT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.